#

Small Cell Lung Cancer

  • Compensation to be determined
  • 13 visits (enrollment open)
#

18+ Years

#
Male or Female
#
Smoker & Non-Smoker

Description

A Randomized, Atezolizumab-Controlled Study to Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).

ES- SCLC (extensive stage small cell lung cancer) is a kind of lung cancer. The cancer cell of ES-SCLC can produce chemicals that cause endocrine abnormality. Most patients present with tumor metastases (cancer cells spread over the body) as the first symptom. Currently, systematic chemotherapy or immunotherapy combined with platinum-based treatment are the primary treatment for ES-SCLC.

The purpose of this study is to compare the effects of the study drug plus chemotherapy with atezolizumab plus chemotherapy on you and your disease.

Is this not what you are looking for?
Check out our other studies.

Related Studies

#

Gout

  • Compensation to be determined
  • Clinical visits 17
#
Between 19+ Years

#
Male or Female
#
Smoker & Non-Smoker
#

Small Cell Lung Cancer

  • Compensation to be determined
  • Clinical visits 24
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
#

COPD

  • Compensation to be determined
  • 12 clinic visits
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
© 2024 Access Research Institute. All Rights Reserved